Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride,Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Proveca
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cessatech and Proveca Announce World-wide Excluding US Commercial Partnership for CT001
Details : Under the agreement, Proveca will be the marketing authorization holder of CT001 worldwide excluding the US, which is being evaluated in the late stage for the treatment of Acute Pain in children.
Brand Name : CT001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 26, 2024
Lead Product(s) : Ketamine Hydrochloride,Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Proveca
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?